ANNEXA-I生物标志物亚组研究:抗Xa因子活性与内源性凝血酶潜力同血肿扩大及动脉血栓事件的相关性
ANNEXA-I试验的生物标志物亚组分析纳入530例与阿哌沙班或利伐沙班相关的颅内出血患者,比较andexanet与常规治疗对抗Xa因子活性和内源性凝血酶潜力(ETP)的影响,并分析其与12小时血肿扩大及30天动脉血栓栓塞事件的关联。结果显示andexanet较常规治疗在1小时更大程度降低抗Xa因子活性、升高ETP;抗Xa因子活性降低与血肿扩大减少独立相关,ETP升高与血肿扩大减少及血栓栓塞事件增加独立相关。
要点
- andexanet较常规治疗1小时抗Xa因子活性降幅更大(中位降低98.3 vs 10.9 ng/mL,P<0.001)。
- andexanet较常规治疗1小时ETP升幅更大(中位升高753.1 vs 126.6 nmol/L-min,P<0.001)。
- 校正后抗Xa因子活性每降低100 ng/mL,血肿扩大OR 0.69(95%CI 0.53-0.92;P=0.010)。
核心结论
- 在阿哌沙班或利伐沙班相关颅内出血患者中,andexanet较常规治疗在1小时产生更大的抗Xa因子活性降低和ETP升高。
- 基线至1小时抗Xa因子活性降低与血肿扩大减少独立相关,1小时ETP升高与血肿扩大减少及血栓栓塞事件增加独立相关。
研究设计与样本
- ANNEXA-I随机试验的二次分析,共纳入530例患者。
- 抗Xa因子活性分析纳入438例有基线结果的患者,ETP分析纳入328例有基线数据者。
- 采用Wilcoxon秩和检验比较andexanet与常规治疗对抗Xa因子活性及ETP变化的影响。
- 血肿扩大采用logistic回归(未校正及校正),血栓栓塞事件采用Cox回归(未校正及校正)。
主要发现
- 1小时抗Xa因子活性中位数:andexanet组8.6 ng/mL vs 常规治疗组97.5 ng/mL;中位较基线降低:andexanet组98.3 ng/mL vs 常规治疗组10.9 ng/mL(P<0.001)。
- 1小时ETP中位数:andexanet组1573.5 nmol/L-min vs 常规治疗组874.5 nmol/L-min;中位较基线升高:andexanet组753.1 nmol/L-min vs 常规治疗组126.6 nmol/L-min(P<0.001)。
- 校正分析中,1小时抗Xa因子活性每降低100 ng/mL与血肿扩大减少相关(OR 0.69,95%CI 0.53-0.92;P=0.010)。
- 校正分析中,1小时ETP每升高100 nmol/L-min与血肿扩大减少相关(OR 0.94,95%CI 0.90-0.99;P=0.019)。
- 校正分析中,1小时ETP每升高100 nmol/L-min与血栓栓塞事件风险相关(OR 1.08,95%CI 1.00-1.16;P=0.047)。
关键数值与推荐
- 血肿扩大定义:12小时血肿体积增加≥12.5 mL或体积百分比变化≥35%。
- 血栓栓塞事件包括缺血性卒中、心肌梗死和系统性栓塞,随访30天。
- 抗Xa因子活性降低的校正因素:症状发作至基线扫描时间、基线舒张压、血肿体积、基线生物标志物水平、基线扫描至治疗时间。
- ETP升高的校正因素:年龄、基线生物标志物水平、既往心肌梗死、是否符合高剂量andexanet治疗条件。
临床怎么用
- 原文未提供临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors) was a randomized trial that demonstrated that andexanet compared with usual care in patients with intracranial hemorrhage associated with FXa (factor Xa) inhibitor treatment reduces the risk of hematoma expansion and increases the risk of arterial thromboembolic events. METHODS: In a secondary analysis of the ANNEXA-I trial, we compared the effects of andexanet with usual care on change in anti-FXa activity and endogenous thrombin potential (ETP) using Wilcoxon rank-sum test. We examined the associations between 1-hour reduction in anti-FXa and 1-hour increase in ETP and hematoma expansion at 12 hours (≥12.5 mL or percentage volume change ≥35%) using logistic regression, both unadjusted and adjusted for time from symptom onset to baseline scan, baseline diastolic blood pressure, hematoma volume, baseline biomarker level and time from baseline scan to treatment, and association with arterial thromboembolic events (ischemic stroke, myocardial infarction, and systemic embolism) during 30 days of follow-up using Cox regression, both unadjusted and adjusted for age, baseline biomarker level, prior myocardial infarction, and eligibility for treatment with high-dose andexanet. RESULTS: ANNEXA-I enrolled 530 patients. Among 438 patients with baseline anti-FXa results, andexanet compared with usual care reduced anti-FXa activity at 1 hour (median, 8.6 versus 97.5 ng/mL; median reduction from baseline, 98.3 versus 10.9 ng/mL; P<0.001). Among 328 patients with baseline ETP data, andexanet compared with usual care increased ETP at 1 hour (median, 1573.5 versus 874.5 nmol/L-min; median increase, 753.1 versus 126.6 nmol/L-min; P<0.001). In adjusted analyses, reduction in anti-FXa at 1 hour was associated with reduced hematoma expansion (per 100 ng/mL: odds ratio, 0.69 [95% CI, 0.53-0.92]; P=0.010), and increase in ETP at 1 hour was associated with reduced hematoma expansion (per 100 nmol/L-min: odds ratio, 0.94 [95% CI, 0.90-0.99]; P=0.019) and risk of thromboembolic events (per 100 nmol/L-min: odds ratio, 1.08 [95% CI, 1.00-1.16]; P=0.047). CONCLUSIONS: In patients with apixaban- or rivaroxaban-associated intracranial hemorrhage, andexanet compared with usual care produces greater reduction in anti-FXa and greater increase in ETP at 1 hour. Reduction in anti-FXa from baseline to 1 hour is independently associated with reduced hematoma expansion, and increase in ETP from baseline to 1 hour is independently associated with both reduced hematoma expansion and increase of thromboembolic events. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03661528.
引用
- Eikelboom JW, Sharma M, Xu L, et al. Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy. Stroke. 2025. PMID: 40289797. doi:10.1161/STROKEAHA.124.049966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。